Navigation Links
New light on Cardiology

The angiotensin-converting enzyme (ACE) inhibitor ramipril, used for the treatment of hypertension, can retrieve, and may even prevent, left ventricular hypertrophy (LVH), thereby lowering the risk of stroke and myocardial infarction (MI), a new study has shown.Results from the landmark Heat Outcome Prevention Evaluation (HOPE) study showed the drug to cause reversal and prevention of LVH in a broad range of patients – those with normal or controlled blood pressure, both with and without coronary heart disease.//

The HOPE study compared the effects of the ACE inhibitor in addition to standard therapy with placebo and vitamin E in a sample of about 7,580 high-risk patients with cardiovascular disease.In the HOPE sub-study, conducted by Dr James Chadwik and colleagues from the University of Baltimore, the electrocardiograms of 6,222 patients at baseline and at the end of the 4.5 year-long study were compared for the presence, regression or development of LVH. Cardiovascular outcomes such as MI, stroke and heart failure were also evaluated.

Among 92.9 per cent of the patients, ramipril either prevented or caused gradual regression of LVH, independent of its effect on blood pressure control. Adverse cardiovascular outcomes were also lower among those who did not develop LVH or experienced regression of their LVH, compared with those in which LVH developed or did not regress. However, 91 per cent of the patients who received a placebo experienced prevention or regression of LVH, which the researchers said was “intriguing” but was more likely to be due to other risk factor modifications among the study participants.

Since the regression of LVH found with the drug was independent of blood pressure reduction, the study authors suspect that ACE inhibitors have a direct effect in causing regression.Dr Gregory Bosen, professor of cardiovascular medicine at City Hospital in England, agrees that the research raises important issues. Dr Chadw ik said that monitoring changes in LVH status by ECG might predict outcomes for patients with the condition. “We think we can now reduce the risk of cardiovascular events and death by regression of LVH using ECG markers. The ECG is easily applied and relatively inexpensive.”


Related medicine news :

1. Doctors operate upon patients in candlelight- latest from the quake scene
2. “Don’t fear long haul flights!” Vascular surgeon tells travelrs
3. Hazards of sunlight
4. Slightly High BP Poses Health Risk
5. Arterial stiffness prevented by light drinking
6. Diet, Sunlight connected to Breast Cancer Risk
7. Dangers of sunlight
8. A ray of light on Cardiology
9. Nightlights could ward diabetic blindness
10. Unborn babies respond to light
11. Sensitive to bright light? You may have sensitive teeth also
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: